BBT-877 is under development as a treatment for various fibrotic diseases.

  • About the drug candidate

    BBT-877 is an orally administered autotaxin enzyme activity inhibitor which is under development as a treatment for various fibrotic diseases such as idiopathic pulmonary fibrosis (IPF).

    Autotaxin is an enzyme that converts lysophosphatidylcholine (LPC), a type of fat in the human body, into lysophosphatidic acid (LPA), which is known to lead to various types of fibrosis. LPA produced by autotaxin is known to bind to receptors in cells and induce various physiological activities, such as neovascularization, sclerosis, tumorigenesis and tumor metastasis.

    BBT-877 is a small-molecule compound that suppresses inflammation and sclerosis by reducing LPA production through the selective inhibition of autotaxin.

    During pre-clinical studies, which utilized an animal disease model with bleomycin induced pulmonary failure, BBT-877 showed superior results in both the Ashcroft score and the collagen deposition when compared to nintedanib’s positive control group and Galapagos NV’s GLPG1690. (Presented at IPF Summit 2018)

    During the US-based clinical trail Phase 1, BBT-877 showed dose proportionate systemic exposure while all dose levels were well tolerated with no serious adverse events (SAEs) reported. The data relating to LPA inhibition in the multi-ascending dose study suggested that 100mg twice daily and 200mg twice daily dosages showed up to 90% LPA inhibition. The Phase I clinical trial results were presented at the postersession of the European Respiratory Society Annual Conference 2019.

    With these pre-clinical and clinical results, Bridge Biotherapeutics signed a collaboration and global license agreement with Boehringer Ingelheim, a leading pharmaceutical company in the idiopathic pulmonary fibrosis treatment market, on July 17, 2019 (upfront and near term payments equating to €45mn and eligible to receive up to more than €1.1bn in potential milestone payments and royalties). Boehringer Ingelheim will lead the ensuing development thereafter.

    Phase I clinical study of BBT-877 has been completed and we are currently conducting drug-drug interaction studies as well as pharmacokinetic studies in Asians in the United States.

    The drug candidate was originally discovered by LegoChem Biosciences and was licensed out through an exclusive distribution and licensing agreement to Bridge Biotherapeutics in 2017.

    Our research results were presented at the following conferences and can be downloaded by clicking the link down below.

    • Event
      Date of Presentation
    • Event

      European Respiratory Society 2019

      Date of Presentation

      2019년 09월 29일

    • Event

      American Thoracic Society 2019

      Date of Presentation

      2019년 05월 20일

    • Event

      IPF Summit 2018

      Date of Presentation

      2018년 08월 22일

  • Clinicalstudy information

  • Ask about the clinical studies

  • What is idiopathicpulmonary fibrosis?

    Idiopathic pulmonary fibrosis (IPF) is a type of interstitial lung disease which results in pulmonary fibrosis for unknown reasons, leading to scarring, shortness of breath, dry cough and gradual loss of lung function.

    Idiopathic pulmonary fibrosis affects 5 million people globally and has an estimated prevalence of 12 per 100,000 persons. Those over 60 are most commonly affected and the average life expectancy following diagnosis is approximately 4 years.

    More information available on NIH (U.S. National Library of Medicine)